Literature DB >> 20346014

The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults.

Anna Kalff1, Claire Dowsing, Andrew Grigg.   

Abstract

Thirteen adult patients aged 22-63 (median 30) years with sickle cell disease (SCD) were enrolled in a regular erythrocytapheresis (ECP) programme at a single institution between December 1998 and November 2008. The indications for enrolment were recurrent painful crises (PC), acute chest syndrome (ACS), silent cortical ischaemia, pulmonary hypertension, multi-organ crises and pregnancy. Endpoints retrospectively evaluated included the incidence of SCD-related acute events requiring hospitalization following and prior to regular ECP, the development of new and progression of pre-existing related end-organ damage, the effectiveness in reducing HbS levels acutely and prior to the next exchange and the transfusion-related complications. Sixteen acute sickle-related events occurred in five patients in 846 months of patient follow-up. In all patients with reliable data available pre-ECP, the frequency of such events was reduced following commencing regular ECP. No patient experienced stroke, multi-organ crises or developed new and/or progression of end-organ dysfunction. Regular ECP reduced HbS levels to the target of <30% immediately post-exchange. Alloimmunization rates were comparable to the literature and ECP was effective in preventing progressive iron overload. Regular ECP was demonstrated to be an effective, well-tolerated therapy for both acute and chronic complications of SCD in adults.

Entities:  

Mesh:

Year:  2010        PMID: 20346014     DOI: 10.1111/j.1365-2141.2010.08150.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

1.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

Review 2.  Sickle cell disease: when and how to transfuse.

Authors:  Jo Howard
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

3.  Reversal of a rheologic cardiomyopathy following hematopoietic stem cell transplantation for sickle cell disease.

Authors:  Vandana Sachdev; Matthew Hsieh; Neal Jeffries; Anna Noreuil; Wen Li; Stanislav Sidenko; Hwaida Hannoush; Emily Limerick; Delon Wilson; John Tisdale; Courtney Fitzhugh
Journal:  Blood Adv       Date:  2019-10-08

Review 4.  Evolving treatment paradigms in sickle cell disease.

Authors:  Ramasamy Jagadeeswaran; Angela Rivers
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Red blood cell transfusion therapy for sickle cell patients with frequent painful events.

Authors:  Lee M Hilliard; Varsha Kulkarni; Bisakha Sen; Cathy Caldwell; Christina Bemrich-Stolz; Thomas H Howard; Amanda Brandow; Emily Waite; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-27       Impact factor: 3.167

Review 6.  Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease.

Authors:  Eric A Gehrie; Paul M Ness; Evan M Bloch; Seema Kacker; Aaron A R Tobian
Journal:  Transfusion       Date:  2017-06-26       Impact factor: 3.157

7.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

8.  The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.

Authors:  Burcu Camcıoğlu; Meral Boşnak-Güçlü; Müşerrefe Nur Karadallı; Şahika Zeynep Akı; Gülsan Türköz-Sucak
Journal:  Case Rep Hematol       Date:  2015-04-28

Review 9.  Spectra Optia® for Automated Red Blood Cell Exchange in Patients with Sickle Cell Disease: A NICE Medical Technology Guidance.

Authors:  Iain Willits; Helen Cole; Roseanne Jones; Kimberley Carter; Mick Arber; Michelle Jenks; Joyce Craig; Andrew Sims
Journal:  Appl Health Econ Health Policy       Date:  2017-08       Impact factor: 2.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.